CHESS

Enrolling By Invitation
99 years or below
All
Phase N/A
1 Location

Brief description of study

Collect safety and efficacy data of MMAE in patients ages 40-90 years with a moderately symptomatic convexity chronic subdural hematoma (CSDH). Subjects will be randomized 1:1 to conventional surgery or MMAE treatment and followed for 180 days (+/- 30 days).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 29 Jun 2026. Study ID: 24-2027
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research